Incentivizing Antibiotic Research and Development by Scandlen-Finken, Leah & Wertheimer, Albert
Volume 6 | Number 1 Article 191
2015
Incentivizing Antibiotic Research and
Development
Leah Scandlen-Finken
Albert Wertheimer
Follow this and additional works at: http://pubs.lib.umn.edu/innovations
INNOVATIONS in pharmacy is published by the University of Minnesota Libraries Publishing.
Recommended Citation
Scandlen-Finken L, Wertheimer A. Incentivizing Antibiotic Research and Development. Inov Pharm. 2015;6(1): Article 191.
http://pubs.lib.umn.edu/innovations/vol6/iss1/7
Student Project POLICY 
 
Incentivizing Antibiotic Research and Development 
Leah Scandlen-Finken, PharmD Candidate and Albert Wertheimer, PhD 
Temple University School of Pharmacy 
 
 
Key words:  Antibiotic resistance, antibiotic development, resistance initiatives, R&D incentives, managed care 
 
Acknowledgments:  This paper was inspired by many including Jason Gallagher, PharmD; Magid Abou-Gharbia, PhD; John Tomayko, 
MD; Neil Fishman, MD; Lauri Fennell; and most significantly Professor Albert Wertheimer, PhD, who had a seemingly endless store 
of inspiration and encouragement. 
 
In some parts of this manuscript, we include screenshots of information publicly available on the Internet. We include these under 
fair use guidelines in which we reproduce them for purposes such as criticism, comment, reporting, teaching, scholarship and 
research. 
 
Abstract 
Antibiotic Resistance is an international threat, killing thousands and infecting millions. Although certain populations may be at an 
increased risk for infections, anyone can find themselves compromised with a multi-drug resistant infection. Treatments are 
becoming more complicated as the bacteria becomes more elusive. Cures are becoming less certain, and the future antibiotic arsenal 
is looking thin. Although there are many talented scientists and capable drug development entities, the funding and returns on 
investment are not sufficient to entice antibiotic research and development.  
 
This paper explores the current situation regarding antibiotic resistance and its casualties, as well as the mechanisms being employed 
to overcome the increase in resistance, and decrease in antibiotic effectiveness. Through analysis of antibiotic research, development, 
and regulation, this paper adds to the discussion by filling in the current gaps regarding the procurement of sustainable funding via 
an insurance model framework. By incentivizing the pharmaceutical industry to invest in antibiotic research, and by guaranteeing 
returns on investment, a global solution to the current antibiotic resistance problem can be contained. 
 
 
 
Introduction 
We are on the dawn of an international crisis.  Infections are getting harder to treat, treatments are becoming more frequent, more 
expensive, and more people are dying.1,2  Multi-drug resistant organisms (MDRO) are being found all over the world.3  Many fear 
that infection treatment may return to a pre-antibiotic era, or a “post-antibiotic era,” a time when tuberculosis, for example, was a 
death sentence.  When the only prescription available was fresh air.4,5,6  According to a BBC report, infections due to MDRO are 
estimated to rise more than tenfold, kill more than cancer currently does by 2050, and cost more than $100 trillion.  Reporters 
believe these figures are an underestimate.7   To make matters worse, there are not enough antibiotics being developed to satisfy 
the current and future needs.8   The reasons for the lack of antibiotic drug development include difficulty developing novel drug 
classes, high costs of drug research and development, a challenging clinical trial drug approval process, and low to negative returns 
on investment.5,9,10   
 
Methods 
A preliminary literature search was done using PubMed.  Articles that dealt with “antibiotic resistance,” “antibiotic research and 
development,” and “international policy and antibiotics” were included.  President Barack Obama’s Executive Order to Combat 
Antibiotic Resistance was analyzed, as well as the recommendations made by the President’s expert advisors regarding antibiotic 
resistance.  Follow-up questions were posed to experts in the field of antibiotic development, and their suggestions were 
investigated.   
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Findings  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibiotic resistance emerges, even with appropriate antibiotic use, due to selection pressures  
that favor heartier, more clever, bacteria (figure 1, 2).11 
http://www.cdc.gov/media/dpk/2013/dpk-untreatable.html 
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Misuse of antibiotics is also common.12  In many countries antibiotics are readily accessible without a prescription.13  Compound this 
with the fact that many patients seek antibiotics for non-bacterial infections, unaware antibiotics will not treat a viral infection such 
as a cold or flu.14  Inappropriate antibiotic use extends beyond humans.  Antibiotics are used, among other reasons, to promote 
growth in livestock in the United States and abroad.15  Such use has been banned in the European Union.16  However, even when 
used under the supervision of a veterinarian, there may be unintended residual consequences, and subsequent transmission of 
antibiotics to the consumer.17 
 
Furthermore, there are not enough antibiotics to keep up with the growing bacterial resistance.  Antibiotic Research and 
Development (R&D) is challenging.10,18  Despite this, new classes of antibiotics are needed, and the current antibiotic pipeline is 
“thin.”18,19  Over the past eight decades, since the inception of antibiotics, there has not been sufficient antibiotic advancement to 
support our cavalier attitude toward infectious disease (table 1).   
 
Table 1: Timeline of the discovery and introduction of antibiotics 
Antibiotic class; example Year of 
discover
y 
Year of 
introduct
ion 
Year 
resistance 
observed 
Mechanism of 
action 
Activity or target species 
Sulfadrugs; prontosil 1932 1936 1942 Inhibition of 
dihydropteroate 
synthetase 
Gram-positive bacteria 
β-lactams; penicillin 1928 1938 1945 Inhibition of cell 
wall biosynthesis 
Broad-spectrum activity 
Aminoglycosides; streptomycin 1943 1946 1946 Binding of 30S 
ribosomal subunit 
Broad-spectrum activity 
Chloramphenicols; 
chloramphenicol 
1946 1948 1950 Binding of 50S 
ribosomal subunit 
Broad-spectrum activity 
Macrolides; erythromycin 1948 1951 1955 Binding of 50S 
ribosomal subunit 
Broad-spectrum activity 
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Tetracyclines; chlortetracycline 1944 1952 1950 Binding of 30S 
ribosomal subunit 
Broad-spectrum activity 
Rifamycins; rifampicin 1957 1958 1962 Binding of RNA 
polymerase β-
subunit 
Gram-positive bacteria 
Glycopeptides; vancomycin 1953 1958 1960 Inhibition of cell 
wall biosynthesis 
Gram-positive bacteria 
Quinolones; ciprofloxacin 1961 1968 1968 Inhibition of DNA 
synthesis 
Broad-spectrum activity 
Streptogramins; streptogramin B 1963 1998 1964 Binding of 50S 
ribosomal subunit 
Gram-positive bacteria 
Oxazolidinones; linezolid 1955 2000 2001 Binding of 50S 
ribosomal subunit 
Gram-positive bacteria 
Lipopetides; daptomycin 1986 2003 1987 Depolarization of 
cell membrane 
Gram-positive bacteria 
Fidaxomicin (targeting 
Clostridium difficile) 
1948 2011 1977 Inhibition of RNA 
polymerase 
Gram-positive bacteria 
Diarylquinolines; bedaquiline 1997 2012 2006 Inhibition of F1FO-
ATPase 
Narrow-spectrum activity 
(Mycobacterium 
tuberculosis) 
 
Nature Reviews Drug Discovery 12, 371-387 (2013), www.nature.com.nrd/journal/v12/n5/fig_tab/nrd3975_T1.html 
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Perhaps in response to the current antibiotic need, the field of antibiotic research, development, regulations, and policy-making is 
an exciting, interdisciplinary, charming, solution-focused, and widely innovative space.19,20   
 
Recently there has been collaboration to find solutions to the combined lack of innovation and increasing threats due to 
antimicrobial resistance.  Due to the work of many skilled and passionate leaders in the antimicrobial resistance specialty, there has 
been substantial progress made through international dialogue.  Bacterial diagnostics have seen recent attention, and are the focus 
of the 2014 Longitudinal Prize.21 Antimicrobial Stewardship is flourishing, and has seen an encouraging push from the Executive 
Branch with President Obama’s recent Executive Order to Combat Antibiotic-Resistance on September 18, 2014.  In this report, 
President Obama requires antimicrobial stewardship initiatives across various health care settings, including long-term care 
facilities.22  President Obama based the executive order on a report, Combating Antibiotic Resistance, developed by an expert panel 
with the President’s Council of Advisors on Science and Technology (PCAST).23   
 
The United States federal government has recognized the threat of antimicrobial resistance (table 2), and has responded in various 
ways.   
 
Table 2: Resistant bacteria and representative infections, alternatives 
Current and Emerging Resistant 
Bacteria 
Type Representative Clinical 
Infections 
Antibiotics 
Associated with 
Resistance 
Treatment Options (as determined 
based on culture & sensitivity, local 
guidelines, clinical presentation) 
Methicillin-resistant 
Staphylococcus aureus (MRSA)  
gram (+) 
cocci 
skin/soft tissue 
infections, UTI, 
bacteremia, toxic shock 
syndrome, pneumonia, 
osteomyelitis, 
endocarditis, meningitis; 
assoc. with IV catheters 
beta-lactam 
antibiotics (eg., 
oxacillin, penicillin, 
nafcillin, 
amoxicillin, and 
most 
cepholosporins) 
erythromycin 
vancomycin 
 
alternatives: linezolid; clindamycin 
(confirm with D-test); daptomycin; 
TMP-SMX; quinupristine-dalfopristin  
Vancomycin inter- 
mediate and resistant 
Staphylococcus aureus 
(VISA/hVISA/VRSA)  
gram (+) 
cocci 
skin/soft tissue 
infections, UTI, 
bacteremia, toxic shock 
syndrome, pneumonia, 
osteomyelitis, 
endocarditis, meningitis 
vancomycin; beta-
lactam antibiotics 
(eg., oxacillin, 
penicillin, nafcillin, 
amoxicillin, and 
most 
cepholosporins) 
erythromycin 
linezolid; clindamycin; daptomycin; 
TMP-SMX; quinupristine-dalfopristin 
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Community-acquired methicillin-
resistant Staphylococcus aureus 
(cMRSA)  
gram (+) 
cocci 
necrotizing pneumonia; 
skin infections, boils, 
abcesses (seen in IV drug 
abusers, athletes who 
share equipment, day 
care centers, military 
personnel; prisons); 
drainage of abscess is 
primary treatment; treat 
with antibiotic only  if 
needed[2] 
beta-lactam 
antibiotics (eg., 
oxacillin, penicillin, 
amoxicillin, and 
most 
cepholosporins, 
erythromycin 
doxycycline or minocycline; 
clindamycin (confirm with D-test); 
linezolid; TMP-SMX  
Streptococcus pneumoniae (multi-
drug resistant)  
gram (+) 
diplo- 
coccus 
pneumonia, otitis media, 
sinusitis, bronchitis, 
bacteremia, peritonitis, 
cellulitis, meningitis, 
arthritis  
 
multi-drug 
resistance; 
penicillin G, 
cephalosporins, 
TMP-SMX, 
erythromycin, 
doxycycline  
for multi-drug resistance consider:  
vancomycin +/- rifampin; 
fluoroquinolone (gemifloxacin, 
moxifloxacin), levofloxacin) 
 
alternatives: linezolid; clindamycin ; 
imipenem/cilastatin 
Escherichia coli (E. Coli) - CTX-M 
extended spectrum beta-
lactamases (ESBL)  
gram (-) 
rod 
UTIs Oral 
cephalosporins, 
TMP/SMX, 
fluoroquinolones 
Fosfomycin , nitrofurantoin, 
ertapenem, doripenem, 
imipenem/cilastatin 
Enterococcus faecium (E. faecium) 
vancomycin resistant enterococci 
(VRE)  
gram (+) 
cocci 
meningitis, UTI, 
bacteremia (central 
venous catheter-related), 
endocarditis 
vancomycin; 
streptomycin; 
gentamicin; 
penicillin; ampicillin 
linezolid; quinupristine-dalfopristin; 
daptomycin, 
fosfomycin (for UTI) 
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Pseudomonas aeruginosa 
(multidrug resistant strains)  
gram (-) 
rod 
UTIs, pneumonias, skin 
and soft-tissue infections, 
endocarditis, meningitis 
imipenem/cila- 
statin, mero- 
penem, non-
antipseudo-monal 
penicillins, oral 
cephalosporins, 
colistin, polymyxin B (for multidrug 
resistant strains) 
Klebsiella pneumoniae  
-extended spectrum beta-
lactamases (ESBL)  
gram (-) 
rod 
pneumonias, UTIs, upper 
respiratory tract 
infections, surgical 
wound infections 
2nd, 3rd generation 
cephalosporins; 
aztreonam; 
carbapenems 
imipenem; meropenem; colistin 
multi-drug resistant 
Mycobacterium tuberculosis 
(MDR-TB)  
acid-fast tuberculosis (lung 
infection) 
isoniazid; rifampin; 
possibly 
streptomycin  
 
 
multiple agents required for 
treatment: 
aminoglycoside (amikacin or 
kanamycin) or polypeptide antibiotic 
(capreomycin) + antimycobacterials 
(pyrazinamide + ethambutol) + 
fluorquinolone (moxifloxacin) + 
rifabutin; other agents may need to 
be substituted based on drug 
availability 
Acinetobacter baumanii  gram (-) 
rod 
immunocompromised 
patients: pneumonia 
(commonly ventilator-
associated), UTI, 
septicemia, central 
venous catheter-related 
infections, traumatic 
wound infections 
imipenem; 
meropenem; 
antipseudomonal 
agents, 
fluoroquinolones, 
carbapenems 
ampicillin-sulbactam; colistin  
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Staphylococcus epidermidis 
(methicillin resistant)  
gram (+) bacteremia, catheter, 
implant, and prostheses-
related infection (biofilm 
formations), endocarditis 
penicillin, 
amoxicillin 
vancomycin  
 
if infected implant, surgical removal 
or replacement may be required; 
vancomycin +/- (rifampin + 
gentamicin) 
 
alternative regimens if vancomycin 
resistant: daptomycin, linezolid 
 
http://www.drugs.com/article/antibiotic-resistance.html#s2 
 
The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for 
Preparedness and Response, in the Department of Health and Human Services, established a Broad Spectrum Antimicrobials (BSA) 
program in April 2010 to address the growing rise of antimicrobial resistance.  The National Institute of Allergy and Infectious 
Diseases (NIAID) has held groundbreaking meetings and contributed funds to antibiotic research.  The Centers for Disease Control 
and Prevention (CDC) has also invested in the cause to contain antibiotic resistance.  There have been attempts from the Food and 
Drug Administration (FDA) to streamline the antibiotic approval process.  The FDA has held a series of talks to address the challenges 
facing the antibiotic approval process, most recently in December 2014.  Results of the meetings have been mixed, but undeniably 
promising in their consideration of recent proposals, including widening the non-inferiority margin, considering a tiered clinical trial 
infrastructure, use of a sufficient historical-control in place of an active control in clinical trials, dual indication evaluation within one 
trial, the possibility of pathogen-focused labeling, and use of a pharmadynamic/pharmakokinetic, in vitro/in vivo, translational study 
in place of a second, randomized control trial normally needed for drug approval.18,19,24,25  Overseas, the European Medicines Agency 
(EMA), the European Union’s version of the FDA, has also contributed substantially to the efforts aimed to curb antibiotic 
resistance.26  Everywhere from Mexico to Scotland seems to recognize the growing need for intervention.27,28,29  
 
Additionally, a number of highly qualified and innovative groups, including international and public-private partnerships that unite 
academia, government, and industry, have come together over the issues of antibiotic resistance.  The Wellcome Trust and the Bill 
and Melinda Gates Foundation have been major contributors in the effort to fund antibiotics research and development.30  New 
Drugs for Bad Bugs (ND4BB) has been developed under the auspice of the Innovative Medicines Initiative (IMI), based in Europe.  
The Antibacterial Resistance Leadership Group (ARLG) has recently formed, and is providing grants to contribute to antibiotic 
development at smaller institutions.31  There is also the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 
and The Infectious Diseases Society of America (IDSA), which pay substantial attention to antibiotic resistance, and have united 
thought leaders across international borders.  The Alliance for the Prudent Use of Antibiotics (APUA) is based in Boston, MA, at Tufts 
University, and boasts international efforts and a comprehensive newsletter.32  There is also the International Society for 
Chemotherapy, Infection, and Cancer (ISC), which has several journals and workgroups that address the challenges of antibiotic 
resistance.  Additionally, The World Health Organization (WHO) has developed surveillance software to monitor international 
resistance patterns.33  Worth noting is the substantial investment made by some leadership and scientists within the pharmaceutical 
industry, when many chose to pull their research and development teams out of the antibiotics game.  Astra Zeneca, Cubist, 
GlaxoSmithKline, F. Hoffman-la Roche, The Medicines Company, Astellas, and Pfizer have been involved in antibiotic development 
despite the challenges described henceforth.34  Interestingly, Merck made a recent decision to acquire the pharmaceutical company 
Cubist, known mostly for its antibiotic Cubicin, for $8.4 billion.35  It is possible Merck’s decision will be rewarded, considering Cubist’s 
very recent approval, on December 22, 2014, of combination drug Zerbaxa, to treat urinary tract and abdominal infections.36 
 
Summary 
Although it is clear that many efforts have been made to preserve the effectiveness of current antibiotics, and foster more antibiotic 
research and development, the challenge remains to create a financial solution.  What remains to be seen is a new economic model 
that would ensure antibiotics research, development, and availability.  Through the IMI’s ND4BB platform, DRIVE-AB (Driving 
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reinvestment in R&D for antibiotics and advocating their responsible use) held its inaugural meeting in Geneva, Switzerland in 
October 2014.  DRIVE-AB is an international group creating and testing new economic models that would enable self-sustaining 
antibiotic research.  One can hope that an answer to self-sustaining antibiotics research will surface through the work of these 
thought leaders.  The following proposal may be worth their consideration, as it lays the foundation for an unconventional economic 
model that would enable self-sustaining antibiotic research through a Central Body, a synthesized payer/financier/surveillance 
entity.37  This model has been inspired, in part, by the revitalized framework developed by the global agricultural research 
partnership, CGIAR.38 
 
Recommendations 
The Central Body 
Create a single, “Central Body,” devoted to antibiotic resistance.  This will allow overhead expenses to be reduced, so that both 
scientific and economic resources can be streamlined.  Within this paper alone, at least five separate groups devoted to antibiotic 
resistance have been mentioned.  While current efforts are admirable, and must continue, within one Central Body it will be possible 
to streamline intellectual efforts, and avoid the unknown simultaneous duplication of important work, making the best use of 
limited resources.   
 
Create a single, “Central Fund,” much like CGIAR has done.38  It will become important to easily document the flow of funds, and 
reduce the duplication of costs encountered by running multiple, not fully synchronous antibiotic resistance entities.30  It should be 
possible for anybody interested in donating money, or doing “a walk to benefit antibiotic resistance,” to donate to antibiotic 
research.  One should be able to donate money as easily to antibiotic research as they would cancer research.  This would 
necessitate that this Central Body be a non-profit entity, attaining 501(c)(3) status.  A model proposing a non-profit industry entity 
has been suggested.39  However, it should not be necessary to restructure the current drug development body within the 
pharmaceutical industry.  The pharmaceutical industry, is already so good at developing drugs, what needs to be done is to fund the 
work from a separate entity, the Central Body, while incentivizing the pharmaceutical industry--allowing them to profit on the 
product they create.  The Central Body could always negotiate a percentage of the profits if it would like.   
 
The Central Body should have a Public Relations (PR) department that can give a face to antibiotic resistance.  That is, to “brand” 
antibiotic resistance.  The goal of this would be to educate the general public about the serious nature of antibiotic resistance, and 
that a world without effective antibiotics is inevitable without intervention.  It is important to bring a sense of value and 
appreciation to antibiotics.  Without a profound shift in the current paradigm, antibiotics will continue to be taken for granted--and 
no one will want to pay what they are worth until it is too late to pay any amount for them.  
 
International government involvement will be necessary, as mentioned in the PCAST Report to the President on Combating 
Antibiotic Resistance.23  As far as the entities that pay for antibiotics, there are two models that seem possible in the United States.  
The following managed care/insurance models could be applied to the federal governments in nations whose federal governments 
pay for pharmaceuticals. 
 
The first Managed Care Model would be to incorporate a single Pharmacy Benefit Manager (PBM) within the Central Body.  This 
single PBM (a pharmacy benefit expert contracted on behalf of the Managed Care Organizations (MCOs), or insurance companies) 
would handle the antibiotic coverage of the entire population of the United States.  This PBM could determine formulary 
management and protocols that fit regional resistance patterns, or let local antimicrobial stewardship entities determine proper 
pharmaceutical use.  Such local to global considerations would be possible if everyone is linked via the Central Body.  This could 
potentially be a way to look at antimicrobial stewardship from an epidemiological level.  The data collected from this central PBM 
could be as robust as the Central Body would realistically like it to be, including diagnostic/morphologic/genetic data, if they would 
like to link diagnostics to billing codes.  A lot of valuable resistance and prescribing data could be documented in a central database, 
and interpreted.  This would be an answer to the PCAST request for effective surveillance and response.23 
 
A second Managed Care Model would be to keep the current PBM/MCO structure intact, but appeal to them that the importance of 
paying more for antibiotics than the PBM/MCO may be used to is imperative.  A good pharmacoeconomic evaluation of the new and 
different pharmaceuticals would be paramount.  As much as the direct costs of antibiotic resistance is a public or federal concern, it 
should be of great concern to the MCOs who are paying for the medical complications due to antimicrobial resistance.  Traditionally 
these two benefits, pharmacy vs. medical, have been siloed from one another, or viewed as separate entities.  The pharmacy side 
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tries to keep their costs down without regard to the medical costs, and vice versa.  Recently the “silo” paradigm has shifted.  The 
pharmacy and medical benefit are merging, especially in regards to the rising cost of specialty pharmaceuticals.40  Today, PBMs, 
including government plans, are paying for very expensive medicines, such as Sovaldi for Hepatitis C, because it is often curative, 
staving off more expensive procedures (i.e. liver transplants) and deleterious side effects of other treatment options.41  Gilead, the 
makers of Sovaldi, have seen $8.55 billion in sales within the first nine months of its launch.42  Sales such as those seen with Sovaldi 
make an important statement regarding the willingness of MCOs to pay more than they have traditionally for hard-to-treat-
infections.  To extrapolate to the antibiotic arena, it seems reasonable that PBMs would pay more for effective antibiotics, in the 
face of resistance, in order to avoid a week long hospital admission to treat a complicated Urinary Tract Infection (cUTI), or longer 
when the untreatable UTI causes the patient to become septic.   
 
It is a fantastic climate to engage PBMs and MCOs in discussions about the possibility of paying more for future antibiotic prospects, 
and to possibly start negotiating payment contracts.  It would behoove the pharmaceutical industry to hire pharmacoeconomists to 
appeal to these MCO entities to explain that although an antibiotic looks expensive, it will save money on the medical side.  It would 
behoove the PBM and MCO, on the other hand, to have a specific antibiotic benefit management individual, or department.  This 
entity should also be part of the antibiotic resistance discussion, and part of the Central Body.  This conversation must be had on all 
sides.   
 
The preceding applies directly to the outpatient setting.  There are logistical benefit/reimbursement hurdles in the inpatient setting.  
Ultimately, however, these pharmaceuticals used in the inpatient setting will need to be paid for by either the PBM or MCO, 
depending on if they fall under the pharmacy or medical benefit, respectively.  The biggest MCO happens to be The Centers for 
Medicare and Medicaid Services (CMS), a federal entity.  The negotiations concerning the value-based reimbursement of novel 
antibiotics could be linked to appropriate antimicrobial stewardship practices, as many other CMS reimbursements are tied to 
performance indicators.  It would be possible to negotiate a contracted price for these drugs so that hospitals could be incentivized, 
via reimbursement contracts, to have these inevitably expensive, novel drugs, to combat antibiotic resistance on their hospital 
formulary.  This would help to avoid the seemingly inevitable market failure of better, necessarily more expensive antibiotics.   
 
Each hospital should be engaged in antimicrobial stewardship at the local level.  If these new pharmaceuticals are effective and are 
needed, and if the infectious disease representatives from the hospital are part of this Central Body, the adoption onto formulary of 
these novel drugs seems promising.  It only makes sense to pay a little more up front to avoid very expensive hospital stays, instead 
of posing the additional risks of developing a hospital acquired bacterial pneumonia, or ventilator acquired bacterial pneumonia 
(HABP/VABP), that we may or may not be able to treat.  Additionally, it would behoove medicare to cover home infusion, allowing 
our older populations in nursing homes to be covered for intravenous antibiotics without the need to be admitted to the hospital, 
where they are prone to subsequent infection and falls. 
 
Create contracts through the Central Body to find and develop needed antibiotics, and let the private sector bid on them.37  The 
Central Body could accept the offer it sees most suitable, and could provide a lump-sum dispersement, or installment payments, to 
the private sector.  This would give the private sector reliable, predictable payments, and would incentivize antibiotic R&D.  As 
would happen when a new building or mall must be built, the main contractor within the private sector could draft scientists or 
entities, such as academic institutions capable of performing pre-clinical or phase-I trials, within the Central Body.  This would all be 
possible if the best minds in antibiotic drug R&D were organized within one central organization, such as the Central Body. 
 
Next, Marketing must be considered.10,43  The Marketing Department within the pharmaceutical company will evaluate the needs of 
the pharmaceutical market, and determine the fate of a drug (i.e. if a chemical entity will finish its development).  If the Marketing 
Department of the pharmaceutical company is not part of The Central Body, they will not be aware of all of the new changes taking 
place in the landscape of antibiotic drug development.  It is imperative to include Marketing in the Central Body.  The Marketing 
department will develop relationships with the PBMs and MCOs to get these novel antibiotics paid for.  Here, as in the MCO/PBM, 
there should be a team, or individual, devoted to antibiotics.  The antibiotic marketplace will be a unique one, and will require a 
specific skill-set and ability to develop good relationships with the government, MCOs/PBMs. 
 
The future is unclear, but one is wise to be hopeful.  Solutions to the economic conundrum that belies the high expense, and low 
return on investment, can be found with cooperation.  When the MCOs agree to pay more for antibiotics, understanding they will 
save resultant pharmacy and medical fees attributable to treatment failures, it will help incentivize the pharmaceutical industry to 
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invest in antibiotic R&D.  When the hospital formulary committees agree to put better antimicrobial options on their formularies, 
because better outcomes result in shorter hospital stays (possibly even limiting a hospital stay to the Emergency Department), it will 
help incentivize the pharmaceutical industry to invest in antibiotic R&D.  When the pharmaceutical industry does not have to lose 
money, and can potentially see returns on their investment, they will invest in antibiotic R&D.  If this can happen, it will not be 
necessary to place our hope of cure in the fresh air, as was done before the advent of antibiotics.  
 
The proposed solutions in this document address the need for a new economic model that enables sustainable antibiotic R&D.  To 
my knowledge, these ideas have not been addressed by the many different thought leaders in the antibiotic resistance spectra, with 
the exception of recommending the need for a new, possibly insurance-based, economic model. 
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